Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06435000 · ClinicalTrials.gov registry record

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

A clinical trial of Stargardt Disease and Stargardt's Disease, sponsored by Splice Bio.

Recruiting
Registry status
75
Enrollment target
20
Study locations

NCT06435000: Recruiting study of Stargardt Disease and Stargardt's Disease, sponsored by Splice Bio.

NCT06435000 is a study of Stargardt Disease and Stargardt's Disease that is actively recruiting participants, run by Splice Bio. The registered enrollment target is 75 participants, below the 87-participant average among 16 other Stargardt Disease trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06435000, a study of Stargardt Disease and Stargardt's Disease, is actively recruiting participants, sponsored by Splice Bio.

RECRUITING
Registry status
75 participants
Enrollment target
20
Study locations

Study Summary

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

Study Locations (20)

Other

  • Universitätsklinikum Bonn, Klinik für Augenheilkunde - Bonn
  • University Eye Hospital Tübingen - Tübingen
  • Leeds Teaching Hospitals NHS Trust - Leeds
  • University of Manchester - The Old St Mary's Hospital - Manchester
  • Oxford Eye Hospital - Oxford

Florida

  • Vitreo Retinal Associates - Gainesville
  • Bascom Palmer Eye Institute - Miami

New York

  • Columbia University Medical Center - New York
  • CUIMC/Edward S. Harkness Eye Institute - New York

California

  • Shiley Eye Institute - San Diego

Colorado

  • UCHealth Sue Anschutz-Rodgers Eye Center - Aurora

Georgia

  • Emory University - Atlanta

Maryland

  • Wilmer Eye Institute, Johns Hopkins University MD 21287 - Baltimore

Massachusetts

  • Massachusetts Eye and Ear Infirmary - Boston

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2024-03-29
Est. Completion 2027-02
Splice Bio

2 total trials

What NCT06435000 shows while recruiting

NCT06435000 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 87-participant average among 16 other Stargardt Disease trials with a reported enrollment target (14% lower).

The record links to 4 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06435000 names 20 study sites across 14 states, led by Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT06435000 about?

NCT06435000 is a clinical study titled "An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene". This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

What is the current status of trial NCT06435000?

This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2024-03-29. Estimated completion is 2027-02.

What conditions does trial NCT06435000 study?

This clinical trial studies the following conditions: Stargardt Disease, Stargardt's Disease, STGD1, Stargardt.

Who is sponsoring clinical trial NCT06435000?

This trial is sponsored by Splice Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06435000 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stargardt Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06435000's enrollment target sits among peer trials

75 6th of 16 higher than 10 of 16 other Stargardt Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stargardt Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06435000, the US trial registry maintained by the National Library of Medicine. NCT06435000 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.